Over the course of the study 211 patients received treatment.
• Patients infected with genotype 1: 98 percent of previously untreated patients had a sustained virologic response at week 12 after the end of therapy.
• Patients infected with genotype 1: 98 percent of previously treated patients who did not have a sustained virologic response with HCV protease inhibitors had a sustained virologic response at week 12 after the end of therapy.
• Patients infected with genotype 2: 92 percent had a sustained virologic response at week 12.
• Patients infected with genotype 3: 89 percent had a sustained virologic response at week 12.
• The most common adverse events included nausea, headache and fatigue.
More Articles on Gastroenterology:
EndoChoice Launches Study to Demonstrate Clinical Significance of Fuse Endoscopy System
5 Current Treatments for Ulcerative Colitis
Dr. Michael Uzer Joins Sarah Bush Lincoln Health Center
